SecBot SecBot
8-K ·Filed Apr 10, 2026

AIM

AIM ImmunoTech Inc.
BEARISH
Impact 6/10
Horizondays Processed6mo ago SEC0001493152-26-016179
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight ▼ Bearish

Traders should monitor for immediate stock sales under the expanded ATM program, which could lead to significant dilution for existing shareholders given the company's small market cap. The timing of this expansion immediately after a prior raise suggests ongoing capital needs.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
AIM ▼ -45.28% at T+60d
SHORT call ✓ call won +45.28% · α vs SPY +54.21% · entry $0.5300 → $0.2900
Entry anchored
Apr 10, 03:59 PM ET
via exchange tick
T+1d
+9.43%
call -9.43% · α -8.22%
$0.5800
settled 7mo ago
T+5d
-7.55%
call +7.55% · α +10.84%
$0.4900
settled 6mo ago
T+20d
-41.51%
call +41.51% · α +49.24%
$0.3100
settled 6mo ago
T+60d
-45.28%
call +45.28% · α +54.21%
$0.2900
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

AIM ImmunoTech Inc. amended its equity distribution agreement with Maxim Group LLC to remove the $3 million cap on its at-the-market (ATM) offering, effectively expanding its shelf registration to $3.41 million. This follows a recent capital raise under the same shelf registration.

Key Financial Metrics

Deal Type
credit_facility

Key Facts

  • Amended Equity Distribution Agreement to remove $3 million cap on ATM offering
  • Simultaneously filed a prospectus supplement to increase the offering size
  • Follows a recent $1.12 million capital raise under the same shelf
  • Company is an emerging growth company with a $4M market cap

Financial Impact

Undisclosed amount raised under expanded shelf, previously sold $2.29 million under $3 million cap

dilutiondebt

Risk Factors

  • Dilution of existing shareholders
  • Downward pressure on stock price from potential share sales
  • Ongoing capital needs despite recent fundraising

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-016179
Exhibit: ex3-1.htm0001493152-26-016179
Exhibit: ex5-1.htm0001493152-26-016179
Document: 0001493152-26-016179-index-headers.html0001493152-26-016179
Document: 0001493152-26-016179-index.html0001493152-26-016179
Document: 0001493152-26-016179.txt0001493152-26-016179
31 reports for AIM
Performance horizon
60% Hit rate @ T+20 9 of 15 directional calls Went positive at some point 13 of 18 best @ T+20▲ +57.69%May 14, 2026
Filters
Rows
Reports for AIM — sortable, filterable
TypeNow
Sep 30, 2026
25d ago
DEF 14A
NEUTRAL ★ 3/10
$0.1877awaiting T+20—$0.1600 (−14.76%)
Sep 22, 2026
4w ago
Press Release
NEUTRAL ★ 3/10
$0.2156 $0.1662▼ −22.91%▼ −22.35%$0.1600 (−25.79%)
Sep 14, 2026
5w ago
8-K
BEARISH ★ 7/10
$0.2100awaiting T+20—$0.1600 (+23.81%)
Aug 11, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$0.2500 $0.2332▼ −6.72%▼ −5.66%$0.1600 (−36.00%)
Aug 10, 2026
10w ago
8-K
BEARISH ★ 5/10
$0.2630awaiting T+20—$0.1600 (+39.16%)
Aug 10, 2026
10w ago
Press Release
BEARISH ★ 5/10
$0.2630awaiting T+20—$0.1600 (+39.16%)
Aug 5, 2026
11w ago
8-K
MIXED ★ 6/10
$0.2800 $0.2346▼ −16.21%▼ −15.61%$0.1600 (−42.86%)
Aug 3, 2026
11w ago
Press Release
NEUTRAL ★ 4/10
$0.2600 $0.2260▼ −13.08%▼ −14.31%$0.1600 (−38.46%)
Jun 24, 2026
17w ago
EFFECT
BEARISH ★ 7/10
$0.3740 $0.2534▲ +32.25%▲ +34.18%$0.1600 (+57.22%)
Jun 18, 2026
18w ago
S-1
BEARISH ★ 7/10
$0.3799 $0.2730▲ +28.14%▲ +28.67%$0.1600 (+57.88%)
Showing 10 of 31

US Market Status

Market Closed — Opens in 1h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers